rs1800961 — HNF4A Thr130Ile

Missense variant in HNF4A causing hepatocyte-specific loss of transcriptional activity; associated with early-onset type 2 diabetes and metabolic syndrome, particularly in Latino and Asian populations

See your personal result for HNF4A

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

HNF4A Thr130Ile — A Hepatocyte Switch With Metabolic Consequences

HNF4A11 HNF4A
Hepatocyte Nuclear Factor 4-Alpha: a master transcription factor that controls hundreds of target genes in the liver, pancreatic beta cells, kidney, and intestine. It sits at the apex of the MODY transcription factor cascade, directly activating HNF1A expression. The Thr130Ile variant (T130I) substitutes threonine for isoleucine at position 130 in the DNA-binding domain — a domain so conserved it is essentially identical across vertebrates. The result is a partial, tissue-selective loss of transcriptional activity that affects the liver more than the pancreas, tilting the metabolic balance toward insulin resistance and dyslipidemia in T allele carriers.

The Mechanism

The p.Thr130Ile substitution falls within the DNA-binding domain of HNF4A. Zhu et al. 200322 Zhu et al. 2003
Zhu Q et al. T130I mutation in HNF-4alpha gene is a loss-of-function mutation in hepatocytes and is associated with late-onset Type 2 diabetes mellitus in Japanese subjects. Diabetologia, 2003 demonstrated that T130I retains normal transcriptional activity in HeLa cells and MIN6 beta-cell-like cells, but shows 27–78% of wild-type activity in HepG2 hepatoma cells and primary cultured mouse hepatocytes. The functional impairment is therefore hepatocyte-specific, not pancreatic — a key distinction from the truly pathogenic MODY1 nonsense variants (e.g. rs137853334, p.Gln277Ter) that ablate activity in all tissues.

In hepatocytes, HNF4A normally drives expression of genes controlling [gluconeogenesis | the production of glucose from non-carbohydrate sources in the fasting state], lipid metabolism (ApoAII, ApoB, ApoCI/II, CETP), and bile acid synthesis. Partial loss of HNF4A activity in the liver disrupts these programs, producing the clinical signature seen in T130I carriers: elevated fasting glucose, insulin resistance, hypertriglyceridemia, and reduced HDL-cholesterol.

The Evidence

The largest analysis of T130I and type 2 diabetes comes from a meta-analysis by Jafar-Mohammadi et al. 201133 meta-analysis by Jafar-Mohammadi et al. 2011
Jafar-Mohammadi B et al. A role for coding functional variants in HNF4A in type 2 diabetes susceptibility. Diabetologia, 2011 combining data from 14,279 cases and 26,835 controls: OR 1.20 (95% CI 1.10–1.30), p=2.1×10⁻⁵. This is a modest but well-replicated effect. The original Japanese discovery cohort (Zhu 2003) found a larger OR of 4.3 in a smaller sample — the larger meta-analytic OR of 1.20 is the more reliable estimate.

Population-specific effects are notable. Granados-Silvestre et al. 201744 Granados-Silvestre et al. 2017
Granados-Silvestre MA et al. Susceptibility background for type 2 diabetes in eleven Mexican Indigenous populations: HNF4A gene analysis. Mol Genet Genomics, 2017 found the T allele at 2.7–16% in Mexican indigenous groups, with a consistent association with hypertriglyceridemia. The variant appears to have been positively selected in some Amerindian populations, possibly conferring metabolic advantage under historical nutritional stress while now contributing to T2D risk in a calorie-dense environment.

A pediatric metabolic syndrome association was documented by García-Rodríguez et al. 202055 García-Rodríguez et al. 2020
García-Rodríguez MH et al. Association of the T130I Variant of the HNF4A Gene with Metabolic Syndrome and Its Components in Mexican Children. Metab Syndr Relat Disord, 2020: OR 2.31 (95% CI 1.10–4.83, p=0.026) for metabolic syndrome in children, with abdominal obesity as the dominant component (OR 1.20). This is the earliest age at which T130I phenotypic consequences have been documented.

The Spanish family study by Cieza-Borrella et al. 201466 Cieza-Borrella et al. 2014
Cieza-Borrella C et al. Early-onset type 2 diabetes mellitus is associated to HNF4A T130I polymorphism in families of central Spain. J Investig Med, 2014 found that T130I carriers in diabetes families had significantly higher HbA1c and fasting glucose than non-carriers, with diabetes onset often triggered by stressful situations and tightly linked to gestational diabetes in female carriers.

Practical Actions

The key implication for T allele carriers is liver-centric metabolic monitoring: fasting lipid panel (particularly triglycerides and HDL), fasting glucose, and HbA1c. The hepatocyte-specific nature of the dysfunction means insulin secretion capacity is less impaired than in full MODY1 patients, but liver-driven insulin resistance and dyslipidemia accumulate over time. Reducing hepatic triglyceride burden — through dietary carbohydrate restriction and omega-3 fatty acids — directly addresses the HNF4A-driven lipid dysregulation pathway.

Homozygous TT carriers are extremely rare (~0.1%) and warrant additional vigilance: both alleles carry the partial loss-of-function, potentially doubling hepatic HNF4A impairment and compounding metabolic risk.

Interactions

HNF4A directly activates HNF1A transcription. Carriers who also have functional variants in HNF1A (rs1169288, Ile27Leu) or HNF1B may have compounded transcription factor cascade disruption. The T130I variant in HNF4A affects the DNA-binding domain, while the truly pathogenic MODY1 nonsense variants (rs137853334) eliminate transactivation entirely — these are mechanistically distinct and should not be conflated in clinical communication.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal HNF4A Normal

No HNF4A Thr130Ile variant detected

You carry two copies of the common threonine allele at HNF4A position 130. This is the population-typical genotype — approximately 94% of people globally share this CC genotype. Your hepatic HNF4A transcriptional activity is not impaired by this variant. Your T2D risk from this specific position is not elevated.

CT T130I Carrier Intermediate

One copy of HNF4A Thr130Ile — modest increased metabolic risk

The hepatocyte-specific nature of the T130I loss-of-function distinguishes this variant from the severe MODY1 nonsense variants that ablate HNF4A activity in all tissues. You retain normal pancreatic HNF4A function, so glucose-stimulated insulin secretion capacity is largely preserved. The primary defect is in hepatic lipid handling and gluconeogenesis regulation.

Family studies (Cieza-Borrella 2014, Yang 2016) have identified MODY-like early-onset diabetes pedigrees with T130I, suggesting that in some genetic backgrounds — particularly when combined with additional metabolic risk variants — the T allele may contribute to earlier-onset disease than typical common T2D. If you have first-degree relatives with young-onset diabetes or a MODY-like phenotype, comprehensive monogenic diabetes panel testing is worth discussing with your physician.

TT Homozygous T130I High Risk

Two copies of HNF4A Thr130Ile — substantially elevated metabolic risk

Homozygous TT individuals have not been studied as a separate subgroup in most published datasets due to the low allele frequency (~1–3% T allele globally means TT frequency ~0.01–0.09%). The best estimate of TT risk comes from the additive model (OR squared ≈ 1.44), but the actual phenotypic severity in TT individuals may be higher given the hepatocyte-specific biochemistry: with no T30 allele remaining, hepatic HNF4A activity could fall to the lower end of the 27–78% range reported for heterozygous cells.

Early metabolic monitoring is particularly important for homozygous carriers. If you also have a family history of early-onset diabetes, MODY-panel testing should be considered to rule out additional monogenic diabetes variants in the same HNF4A-HNF1A cascade.